Biocon Q1 Profit Soars 348%, Shares Rise

Biocon Ltd. shares advanced by nearly 3% during early trading on Thursday, driven by the biopharmaceutical company’s robust first-quarter earnings. This surge stemmed from consistent growth across its core biopharma businesses.

The stock traded at Rs 434.1 per share on the NSE around 11 am, marking an increase from its previous close of Rs 425.2. Investors are closely observing whether the biosimilars and generics segments can sustain this earnings momentum in the coming quarters.

Q1 Financial Performance Overview

• Consolidated net profit reached Rs 141 crore for the quarter ending June 30.
• This represents a substantial 348.4% increase compared to Rs 31.4 crore in the same period last year.
• Revenue from operations climbed by 10% year-on-year, totaling Rs 4,336 crore.
• This is up from Rs 3,942 crore reported in the prior year.

Biocon’s operating performance remained stable, with an Ebitda margin of 19.53% for the quarter, a slight increase from 19.43% year-over-year. The company highlighted that its biosimilars and generics businesses were the primary drivers of this quarterly performance, countering broader industry challenges.

Market Trajectory & Valuation

• Biocon shares have shown a steady upward trend, surging by more than 71% over the past three years.
• The stock has gained over 20% in the last year alone.
• As of the preceding session’s close, the stock traded at a price-to-earnings multiple of 166.4 times.
• The company’s market capitalization stood at Rs 70,476 crore.